Oasmia Pharmaceutical AB represents values of innovation, quality, and patient-centricity in the pharmaceutical industry. With a strong corporate philosophy that prioritizes scientific expertise and new drug development, Oasmia Pharmaceutical AB is dedicated to improving patient outcomes and addressing unmet medical needs. By leveraging its unique drug delivery platform technology, Oasmia Pharmaceutical AB strives to deliver effective and safe treatment options to patients worldwide. With a focus on research and development, collaboration, and commercialization of its innovative products, Oasmia Pharmaceutical AB aims to make a lasting impact in the healthcare sector while maintaining high standards of ethics and integrity.

Oasmia Pharmaceutical AB is primarily present in Sweden, as it is a Swedish-based pharmaceutical company.

Some significant milestones achieved by Oasmia Pharmaceutical AB include the successful development and commercialization of several innovative pharmaceutical products. The company has obtained regulatory approvals for its lead product, Apealea, in various countries for the treatment of ovarian cancer. Additionally, Oasmia Pharmaceutical AB has entered into strategic partnerships and collaborations to expand its product portfolio and global reach. These milestones highlight the company's commitment to advancing medical treatments and its dedication to improving patient outcomes. Oasmia Pharmaceutical AB continues to pursue new opportunities and aims to make further progress in the field of oncology and other therapeutic areas.

Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in developing and commercializing novel cancer treatments. Founded in 1998, Oasmia has made significant advancements in therapeutic areas such as ovarian cancer, breast cancer, and prostate cancer. The company's primary focus is on creating innovative anticancer drugs based on their patented technology, XR17. Oasmia leads the way in providing effective treatments with fewer side effects, aiming to improve patients' quality of life. With a strong commitment to research and development, Oasmia Pharmaceutical AB strives to make a lasting impact in oncology treatment globally.

The main competitors of Oasmia Pharmaceutical AB in the market include AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, and Novartis AG.

Oasmia Pharmaceutical AB is primarily active in the pharmaceutical industry.

The business model of Oasmia Pharmaceutical AB focuses on developing, manufacturing, and commercializing new generation drugs within human and veterinary oncology. Oasmia Pharmaceutical AB aims to improve treatment options for cancer with its unique drug delivery platform, XR-17, which enhances the efficacy and safety of existing chemotherapeutic agents. The company collaborates with international pharmaceutical partners to make its drugs available to patients worldwide. Oasmia Pharmaceutical AB combines innovative research and development with strategic partnerships to bring novel oncology treatments to the market.

Vivesto KGV ir -2,25.

Vivesto KUV ir 0.

AlleAktien kvalitātes vērtējums Vivesto ir 1/10.

Pašreiz nevar aprēķināt apgrozījumu Vivesto.

gaidāmā Vivesto peļņa ir -54,88 milj. SEK.

Oasmia Pharmaceutical AB is a leading pharmaceutical company specialized in the development and commercialization of drugs for the treatment of cancer and other serious diseases. The company is headquartered in Uppsala, Sweden, and is listed on the NASDAQ Stockholm. Oasmia Pharmaceutical's business model is primarily based on the development and sale of innovative drugs for cancer treatment. The company focuses on the development of drugs based on its proprietary nanotechnology platform XR-17, which allows for increasing the efficacy of cancer drugs while reducing their negative impacts on the body. Through this platform, the company has successfully developed and launched its first product Paclical, a safe and effective drug for the treatment of breast cancer, ovarian cancer, and lung cancer. Oasmia Pharmaceutical also has a second division based on the manufacturing and commercialization of veterinary drugs primarily used for small animals. In particular, the company has developed and launched a range of products for the treatment of diseases in dogs and cats, such as bone marrow cancer. To develop and market new products, Oasmia Pharmaceutical collaborates closely with various institutions and companies, such as Uppsala University. The company also has a strong pipeline in this division, focusing on the development of drug candidates for the treatment of prostate cancer, ovarian carcinoma, and adenocarcinoma. The company is committed to regularly expanding its portfolio and increasing market share. The company has also decided on a strategic expansion into new markets. Recently, Oasmia Pharmaceutical has entered into two important partnerships to bring its products and services to the US and Asian markets. These partnerships will help establish Oasmia Pharmaceutical as a provider of innovative drugs in these regions. Overall, Oasmia Pharmaceutical AB is a company specializing in the development of drugs for the treatment of cancer and other serious diseases. The company consists of two main divisions focused on the development of human and veterinary drugs. It also has a strong pipeline of drug candidates and collaborates closely with various institutions and companies to develop and market new products and services. Through its focus on innovative technologies and partnerships, Oasmia Pharmaceutical AB is on track to solidify its position as a leading pharmaceutical company.

Vivesto izmaksā dividendes 0 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Vivesto vai uzņēmums nedod dividendes.

Vivesto ISIN ir SE0000722365.

Vivesto WKN ir 509722.

Vivesto simbols ir VIVE.ST.

Pēdējo 12 mēnešu laikā Vivesto maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Vivesto plāno maksāt dividendes 0 SEK apmērā.

Vivesto pašreizējā dividendu rentabilitāte ir .

Vivesto maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Vivesto pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 SEK. Tas atbilst dividendes ražībai 0 %.

Vivesto tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Vivesto apmērā 0 SEK, kas tika izmaksāta 24.06.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 24.06.2025..

Pēdējās dividendes izmaksa notika 24.06.2025..

Gadā 2024, Vivesto izmaksāja 0 SEK dividendes.

Vivesto dividendes tiek izmaksātas SEK.